Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Oriola

1.19 EUR

+0.34 %

7,737 following

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+0.34 %
+3.83 %
+9.14 %
+6.04 %
+10.15 %
+25.68 %
-32.31 %
-39.45 %
-35.09 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
221.28M EUR
Turnover
66.49K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Accumulate
Target price
Updated
31.10.2025
Disclaimer
Rauli Juva
Rauli Juva

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.2.
2026

Annual report '25

25.3.
2026

General meeting '26

29.4.
2026

Interim report Q1'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Third party research

Oriola: Earnings turning positive - Evli

Oriola posted good Q3 results, with a key positive the faster recovery than we had expected recovery of profitability in the Wholesale segment. With good development across the board, earnings also turned positive. We raise our target price to EUR 1....

Oriola
Third party research

Oriola: Good development across the board - Evli

Oriola posted good figures in Q3. Net sales growth was nearly in the double-digits, while the adj. EBITDA of EUR 9.6m exceeded our EUR 9.1m expectations. Profitability was aided by faster than anticipated profitability recovery of the Wholesale-segment...

Oriola
Third party research

Oriola: Growth in place, profitability next - Evli

Oriola saw solid growth in Q2, and we anticipate a continued good growth pace in Q3. We expect the weaker profitability in the Wholesale-segment to improve gradually during the second half of the year, enabling y/y group level improvement.

Oriola
Third party research

Oriola: Profitability drivers in place - Evli

Solid growth, profitability on previous year levels Oriola posted solid growth figures in Q2, while profitability development remained modest. Net sales growth exceeded our expectations, up 12% y/y to EUR 493.9m (EUR 473.7m/496.7m Evli/cons.). The adj...

Oriola
Third party research

Oriola: Eyeing gradual improvements - Evli

Oriola More cautious stance on Wholesale profitability Oriola reports its Q2 results on July 18th. Performance in Q1 was fairly good but mixed. While the Distribution-segment continued to show good growth and volume driven profitability improvements ...

Oriola
Forum discussions
Hello Inderes community! Greetings from Oriola’s IR team. It is important to us that our investor communications serve all stakeholders as well as possible – including private investors. Last week, we announced an investment in a new distribution center in Järvenpää as well as a ...
1/9/2026, 1:33 PM
25
The strategy is, in my opinion, quite clear in itself, but its credibility is still weak. It will certainly improve if the large projects are successfully completed. After all, credibility must be earned. Oriola would be a more attractive investment if they could exit the associate...
yesterday
by tj_hodl
9
Here are Atte’s comments on Oriola’s distribution center plans and the key themes of the upcoming strategy. On Wednesday, Oriola announced that it is making a significant investment in a new distribution center in Järvenpää. The core idea of the investment is to improve Oriola’s ...
1/8/2026, 7:41 AM
by Sijoittaja-alokas
8
Excellent opening from the company’s IR; points just for the fact that you want feedback from retail investors as well. One concrete suggestion is that since Oriola lists a few analysts covering the company, could those analyses be made available on the company’s website? For example...
1/10/2026, 6:38 AM
by Makex
6
Rauli has prepared a new company report on Oriola after the Q3 results were
10/31/2025, 5:43 AM
by Sijoittaja-alokas
6
Here are Rauli’s comments on the write-down of Kronans’ value. Oriola’s joint venture Kronans Apotek is recording an impairment related to delays in the integration and ERP project. In practice, this means that the company’s own assessment of the joint venture’s value has decreased...
12/19/2025, 2:37 PM
by Sijoittaja-alokas
5
Here are Rauli’s comments regarding Oriola preparing for a new distribution center. Oriola announced yesterday that it would initiate change negotiations with the entire staff of its Espoo office regarding the construction of a new distribution center in Järvenpää. However, the investment...
11/18/2025, 7:06 AM
by Sijoittaja-alokas
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.